Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q1 2026 · 10-Q
Revenue$51.72M$51.72M+14.1% vs Q1 2025 Net Income-$13.35M-$13.35MN/M vs Q1 2025 EPS Diluted-$0.67-$0.67N/M vs Q1 2025 Operating Income$17,368,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
Free Cash Flowderived$48,463,000N/M Margins · derivedOperating margin33.6%+113.5 pt vs Q1 2025
Net margin-25.8%+67.8 pt vs Q1 2025
ended Mar 31, 2026 · filed May 8, 2026 · 38 d after period end